Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 3, 1997, Pages 301-311

  Amantea, Michael A ^a   Forrest, Alan ^b   Northfelt, Donald W ^b   Mamelok, Richard ^b  

^a ALZA CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KAPOSI SARCOMA; MALE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CROSS-OVER STUDIES; DOXORUBICIN; DRUG CARRIERS; HUMANS; LINEAR MODELS; LIPOSOMES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 0030898351     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90162-4     Document Type: Article

References (31)

1. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;1:123-8.
2. Miles SA, Wang H, Elashoff R, Mitsuyasu RT. Improved survival for patients with AIDS-related Kaposi's sarcoma. J Clin Oncol 1994;12:1910-6.
3. Gill PS, Akil B, Colletti P, Rarick M, Loureiro C, Bernstein-Singer M, et al. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 1989;87:57-61.
4. Plettenberg A, Stoehr A, v Dyk U, Albrecht H, Stellbrink HJ, Meigel W. Increasing risk for opportunistic infections (CDC IV C1) during chemotherapy in patients with Kaposi's sarcoma. IX International Conference on AIDS 1993; Berlin, Germany, PO-B12-1557.
5. Gabizon A, Chisin R, Amselem S, Druckmann S, Cohen R, Goren D, et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. Br J Cancer 1991;64:1125-32.
6. Gabizon A, Barenholz Y, Bialer M. Prolongation of circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993;10:703-8.
7. Huang SK, Mahew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52: 6774-81.
8. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993;143:10-4.
9. Vaage J, Barberá-Guillem E, Abra R, Huang A, Working P. Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer 1994;73:2366-71.
10. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, et al. Pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's Sarcoma. J Clin Pharmacol 1996;36:55-63.
11. Prévost G. Estimation of a normal probability density function from samples measured with non-neglible and non-constant dispersion 1977. Internal Report, AdersaGerbios, 2 avenue du ler mai, F-91120 Palaiseau, France.
12. Stiemer JL, Mallet A, Golmard J, Boisieux J. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effect model. Drug Metab Rev 1984;15:265-92.
13. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15:153-71.
14. Forrest A, Ballow CH, Nix DE, Birmingham MC, and Schentag JJ. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37:1065-72.
15. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
16. D'Argenio DZ, Schumitzky A. Adapt users guide 1992. Los Angeles: Biomedical Simulations Resource, University of California, 1992.
17. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Jusko WJ, and Schentag JJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:1-43.
18. Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometika 1979;66:237-42.
19. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immunodeficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-7.
20. Classification and regression tree (CART) analysis. Evanston, IL: Systat, 1992.
21. Speth PAJ, van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
22. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983;43:3417-21.
23. Speth PAJ, Linssen PCM, Holdrinet RSG, Haanen C. Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six hour continuous infusions. Clin Pharmacol Ther 1987;41:661-5.
24. Landaw EM, DiStefane JJ. Multiexponential, multi-compartment, and noncompartmental modeling; II: data analysis and statistical considerations. Am J Physiol 1984;15:R665-77b.
25. Riggs CE, Benjamin RS, Serpick AA, Bachur NR. Biliary disposition of adriamycin. Clin Pharmacol Ther 1977;22:234-41.
26. Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977;37:1416-20.
27. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992;52:5135-43.
28. Shubik P. Vascularization of tumors: a review. J Cancer Res Clin Oncol 1982;103:211-26.
29. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
30. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992;9:135-87.
31. Vogel J, Henricks SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988;335:606-11.